Physician profile
Raphael A Castillo
NPI 1770664294
$8,498.97
in general payments reported to CMS, 2019-2025
24 companies · $2,972 in 2025
The $2,972 reported for 2025 was more than what 91% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $789 · 2020: $256 · 2021: $215 · 2022: $1,064 · 2023: $1,245 · 2024: $1,958 · 2025: $2,972.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,174.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,352.33 | 2023-2025 | Xiidra, Miebo, Envista Mx60 Iol |
| Alcon Vision LLC | $840.33 | 2020-2025 | Rocklatan, Hydrus Microstent, Rhopressa |
| Sun Pharmaceutical Industries INC. | $712.27 | 2019-2025 | |
| Abbvie INC. | $687.39 | 2022-2025 | Alphagan P, Lumigan, Vuity |
| Allergan, INC. | $661.84 | 2019-2021 | |
| Genentech USA, INC. | $605.60 | 2022-2023 | Vabysmo |
| Biotissue Holdings INC. | $475.57 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $387.78 | 2019-2024 | Eylea Hd |
| Lensar, INC. | $357.99 | 2025 | Lensar Laser System |
| Glaukos Corporation | $329.40 | 2023 | |
| Harrow Eye, LLC | $286.74 | 2024-2025 | Vevye |
| Novartis Pharmaceuticals Corporation | $256.01 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $230.64 | 2024-2025 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $217.62 | 2019-2023 | Tecnis Iol, Tecnis Iol, Catalys System |
| Rayner Intraocular Lenses Limited | $195.84 | 2024-2025 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $190.90 | 2023-2025 | Izervay |
| Amgen INC. | $166.97 | 2024-2025 | Tepezza |
| Oyster Point Pharma, INC. | $150.97 | 2023-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Rxsight INC | $146.70 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Light Adjustable Lens (Lal) |
| Horizon Therapeutics Plc | $123.88 | 2023 | Tepezza |
| Apellis Pharmaceuticals, INC. | $49.98 | 2022-2024 | Syfovre |
| Kala Pharmaceuticals, INC. | $36.47 | 2019 | |
| Dompe US, INC. | $21.17 | 2024 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raphael Castillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.